Applicant, as named in the Orange Book

Soleno

Neurocrine Biosciences Inc · Nasdaq: NBIX

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Vykat Xr on 12 Nov 2035. 1 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Vykat Xr NDA 216665 · 3 strengths diazoxide choline	diazoxide choline	12 Nov 2035 patent, carve-out possible	patent, carve-out possible

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.